PremiumThe FlyBeiGene reports Q1 GAAP EPS 1c, consensus (74c) BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B BeiGene says USPTO invalidates Pharmacyclics’ ‘803 patent PremiumThe FlyBeiGene receives positive CHMP opinion for Tevimbra BeiGene price target raised to $259 from $207 at Bernstein BeiGene’s Strong Market Position and Growth Potential: A Buy Rating by Reni Benjamin PremiumThe FlyBeiGene granted orphan designation for sonrotoclax BeiGene price target raised to $313 from $259 at Macquarie BeiGene price target raised to $348 from $345 at Guggenheim 
